• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

创新疗法抗击新冠疫情的前景

Prospects of Innovative Therapeutics in Combating the COVID-19 Pandemic.

作者信息

Mahendran Thamby Rajah, Cynthia Binsin, Thevendran Ramesh, Maheswaran Solayappan

机构信息

School of Biological Sciences, Universiti Sains Malaysia, 11800, Minden, Penang, Malaysia.

Centre of Excellence for Nanobiotechnology & Nanomedicine (CoExNano), Faculty of Applied Sciences, AIMST University, 08100, Bedong, Kedah, Malaysia.

出版信息

Mol Biotechnol. 2025 Jul;67(7):2598-2606. doi: 10.1007/s12033-024-01240-4. Epub 2024 Aug 1.

DOI:10.1007/s12033-024-01240-4
PMID:39085563
Abstract

The sudden global crisis of COVID-19, driven by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), demands swift containment measures due to its rapid spread and numerous problematic mutations, which complicate the establishment of herd immunity. With escalating fatalities across various nations no foreseeable end in sight, there is a pressing need to create swiftly deployable, rapid, cost-effective detection, and treatment methods. While various steps are taken to mitigate the transmission and severity of the disease, vaccination is proven throughout mankind history as the best method to acquire immunity and circumvent the spread of infectious diseases. Nonetheless, relying solely on vaccination might not be adequate to match the relentless viral mutations observed in emerging variants of SARS-CoV-2, including alterations to their RBD domain, acquisition of escape mutations, and potential resistance to antibody binding. Beyond the immune system activation achieved through vaccination, it is crucial to develop new medications or treatment methods to either impede the infection or enhance existing treatment modalities. This review emphasizes innovative treatment strategies that aim to directly disrupt the virus's ability to replicate and spread, which could play a role in ending the SARS-CoV-2 pandemic.

摘要

由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引发的全球突发新冠危机,因其迅速传播和众多有问题的突变,需要迅速采取遏制措施,这些突变使群体免疫的建立变得复杂。随着各国死亡人数不断攀升且看不到可预见的终点,迫切需要迅速开发可快速部署、快速且具有成本效益的检测和治疗方法。虽然已采取各种措施来减轻疾病的传播和严重程度,但在人类历史上,疫苗接种被证明是获得免疫力和避免传染病传播的最佳方法。然而,仅依靠疫苗接种可能不足以应对在SARS-CoV-2新出现变体中观察到的持续不断的病毒突变,包括其受体结合域(RBD)的改变、逃逸突变的获得以及对抗体结合的潜在抗性。除了通过疫苗接种激活免疫系统外,开发新的药物或治疗方法以阻止感染或增强现有治疗方式至关重要。本综述强调旨在直接破坏病毒复制和传播能力的创新治疗策略,这可能在终结SARS-CoV-2大流行中发挥作用。

相似文献

1
Prospects of Innovative Therapeutics in Combating the COVID-19 Pandemic.创新疗法抗击新冠疫情的前景
Mol Biotechnol. 2025 Jul;67(7):2598-2606. doi: 10.1007/s12033-024-01240-4. Epub 2024 Aug 1.
2
Emerging Variants of SARS-CoV-2 and Novel Therapeutics Against Coronavirus (COVID-19)严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的新变种及针对冠状病毒(COVID-19)的新型疗法
3
Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.全面描述了针对 SARS-CoV-2 刺突蛋白的抗体反应,发现了除轻度感染诱导的表位之外的其他疫苗诱导的表位。
Elife. 2022 Jan 24;11:e73490. doi: 10.7554/eLife.73490.
4
Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects.严重急性呼吸系统综合征冠状病毒 2 刺突(S)蛋白疫苗候选物:现状与未来展望。
Rev Med Virol. 2021 May;31(3):e2183. doi: 10.1002/rmv.2183. Epub 2020 Oct 15.
5
COVID-19 CG enables SARS-CoV-2 mutation and lineage tracking by locations and dates of interest.COVID-19 CG 通过关注的地点和日期来实现 SARS-CoV-2 的突变和谱系追踪。
Elife. 2021 Feb 23;10:e63409. doi: 10.7554/eLife.63409.
6
Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics.常见突变对 SARS-CoV-2 刺突 RBD 及其配体人 ACE2 受体结合亲和力和动力学的影响。
Elife. 2021 Aug 26;10:e70658. doi: 10.7554/eLife.70658.
7
COVID-19 Infection: Targeting Possibilities for Treatment.COVID-19 感染:治疗目标的可能性。
Crit Rev Ther Drug Carrier Syst. 2021;38(3):75-115. doi: 10.1615/CritRevTherDrugCarrierSyst.2021035392.
8
Broad-Spectrum Anti-coronavirus Vaccines and Therapeutics to Combat the Current COVID-19 Pandemic and Future Coronavirus Disease Outbreaks.广谱抗冠状病毒疫苗和疗法以应对当前的 COVID-19 大流行和未来的冠状病毒疾病爆发。
Stem Cell Reports. 2021 Mar 9;16(3):398-411. doi: 10.1016/j.stemcr.2020.12.010.
9
A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.一种基于三聚体 RBD 的马赛克型 COVID-19 疫苗候选物可诱导针对奥密克戎和其他 SARS-CoV-2 变体的强大中和作用。
Elife. 2022 Aug 25;11:e78633. doi: 10.7554/eLife.78633.
10
Vaccine-escape and fast-growing mutations in the United Kingdom, the United States, Singapore, Spain, India, and other COVID-19-devastated countries.疫苗逃逸和快速突变在英国、美国、新加坡、西班牙、印度和其他受 COVID-19 肆虐的国家。
Genomics. 2021 Jul;113(4):2158-2170. doi: 10.1016/j.ygeno.2021.05.006. Epub 2021 May 15.

本文引用的文献

1
N-dihydrogalactochitosan serves as an effective mucosal adjuvant for intranasal vaccine in combination with recombinant viral proteins against respiratory infection.N-二氢半乳糖壳聚糖作为一种有效的黏膜佐剂,与重组病毒蛋白联合用于针对呼吸道感染的鼻内疫苗。
Acta Biomater. 2024 Feb;175:279-292. doi: 10.1016/j.actbio.2023.12.039. Epub 2023 Dec 29.
2
Oral delivery of a chitosan adjuvanted COVID-19 vaccine provides long-lasting and broad-spectrum protection against SARS-CoV-2 variants of concern in golden hamsters.壳聚糖佐剂 COVID-19 疫苗经口服给药可提供针对金黄地鼠 SARS-CoV-2 关切变异株的长效和广谱保护。
Antiviral Res. 2023 Dec;220:105765. doi: 10.1016/j.antiviral.2023.105765. Epub 2023 Nov 28.
3
N-dihydrogalactochitosan reduces mortality in a lethal mouse model of SARS-CoV-2.
N-二氢半乳糖壳聚糖降低 SARS-CoV-2 致死性小鼠模型的死亡率。
PLoS One. 2023 Aug 8;18(8):e0289139. doi: 10.1371/journal.pone.0289139. eCollection 2023.
4
Silver N-heterocyclic carbene complexes are potent uncompetitive inhibitors of the papain-like protease with antiviral activity against SARS-CoV-2.银氮杂环卡宾配合物是木瓜蛋白酶样蛋白酶的有效非竞争性抑制剂,对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)具有抗病毒活性。
RSC Med Chem. 2023 May 16;14(7):1260-1271. doi: 10.1039/d3md00067b. eCollection 2023 Jul 20.
5
Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection.对体液免疫受损且SARS-CoV-2持续感染的患者采用瑞德西韦与奈玛特韦/利托那韦联合抗病毒治疗。
Hematol Oncol. 2023 Dec;41(5):904-911. doi: 10.1002/hon.3206. Epub 2023 Jul 15.
6
Inhibition of Toxic Shock Syndrome-Associated by Probiotic Lactobacilli.益生菌乳杆菌抑制中毒性休克综合征相关毒素。
Microbiol Spectr. 2023 Aug 17;11(4):e0173523. doi: 10.1128/spectrum.01735-23. Epub 2023 Jul 5.
7
Structural changes in the SARS-CoV-2 spike E406W mutant escaping a clinical monoclonal antibody cocktail.SARS-CoV-2 刺突 E406W 突变体逃避临床单克隆抗体鸡尾酒的结构变化。
Cell Rep. 2023 Jun 27;42(6):112621. doi: 10.1016/j.celrep.2023.112621. Epub 2023 May 26.
8
Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy.单克隆抗体治疗产生的 SARS-CoV-2 逃逸突变。
Nat Commun. 2023 Jun 7;14(1):3334. doi: 10.1038/s41467-023-37826-w.
9
Combination regimen of nirmatrelvir/ritonavir and molnupiravir for the treatment of persistent SARS-CoV-2 infection: A case report and a scoping review of the literature.尼马瑞韦/利托那韦与莫努匹韦联合治疗持续性 SARS-CoV-2 感染:病例报告和文献综述。
Int J Infect Dis. 2023 Aug;133:53-56. doi: 10.1016/j.ijid.2023.04.412. Epub 2023 May 5.
10
Suramin binds and inhibits infection of SARS-CoV-2 through both spike protein-heparan sulfate and ACE2 receptor interactions.苏拉明通过与刺突蛋白-肝素硫酸和 ACE2 受体的相互作用结合并抑制 SARS-CoV-2 的感染。
Commun Biol. 2023 Apr 8;6(1):387. doi: 10.1038/s42003-023-04789-z.